Nkarta initiates trial of NKX019 in lupus erythematosus

Nkarta announced that researchers at Columbia University Irving Medical Center have initiated an investigator-sponsored trial of NKX019, Nkarta’s allogeneic, CD19-directed chimeric antigen receptor NK-cell therapy in patients with systemic lupus erythematosus, or SLE. The trial broadens the clinical evaluation of NKX019 in lupus. Patient screening is underway. Systemic lupus erythematosus is an autoimmune disease that causes the body’s immune system to attack its own tissues.